M3554 in advanced solid tumors incl. soft-tissue sarcomas

 

Trial name: Anti-GD2 ADC M3554 in Advanced Solid Tumors
Agents: M3554
Phase I
Status Recruiting
Sponsor EMD Serono Research & Development Institute, Inc.

 

This Phase I trial is testing the safety, dosage, and effectiveness of a new targeted therapy, M3554, for people with advanced cancers incl. soft tissue sarcomas.

Further information can be found on clinicaltrials.gov.

 

WHO is the trial for?
  • Confirmed diagnosis of locally advanced or metastatic soft tissue sarcoma that cannot be operated
  • Patients whose tumor as progressed after at least one prior line of systemic therapy for the metastatic setting including anthracyclines
  • Overall health status has to be good (ECOG below or equal to 1)

WHAT is the key question that this trial is attempting to answer?

 This study aims to determine the best dose of a new treatment, M3554, and to check its safety and early signs of effectiveness in treating soft tissue sarcoma (STS) and a type of brain cancer called glioblastoma (IDH-wildtype).

WHY patients might want to participate?

 This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcomas and potentially help other patients with this disease.

The trial might or might not have benefit in your individual case.

WHEN will the trial be open?

 The study is open for recruitment.

WHERE is the trial available?

 The trial is currently active in Japan. Further sites are planned in Belgium, France and the US.

Please check for current information here.

STUDY DESIGN: What does the study look like?

 M3554 will be given at gradually higher doses to find the highest dose that is safe and well-tolerated by participants with soft tissue sarcoma (STS) and glioblastoma (a type of brain cancer). This will be done in two groups: one for STS and one for glioblastoma.

HOW do I get more information?

 Patient organizations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organizations serving sarcoma patients. If there are no such organization in your country, please email us for more information: info@sarcoma-patients.org

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken